Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01359605 · ClinicalTrials.gov registry record · Phase 1
Study to Assess the Metabolism and Elimination of [14C]-Labeled Varespladib Methyl in Healthy Male Subjects
A Phase 1 study, sponsored by Anthera Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT01359605 is a Phase 1 study that has completed, run by Anthera Pharmaceuticals. The registered enrollment target is 6 participants.
The verdict
NCT01359605, a Phase 1 study, has completed, sponsored by Anthera Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of the study is to characterize the metabolism and excretion (ADME) of a single oral dose of \[14C\]varespladib methyl.
Interventions
- DRUG varespladib methyl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2011-06 |
| Est. Completion | 2011-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01359605
The ClinicalTrials.gov registry entry for NCT01359605 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Anthera Pharmaceuticals, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which varespladib methyl is the first listed.
NCT01359605 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01359605 about?
NCT01359605 is a clinical study titled "Study to Assess the Metabolism and Elimination of [14C]-Labeled Varespladib Methyl in Healthy Male Subjects". The purpose of the study is to characterize the metabolism and excretion (ADME) of a single oral dose of \[14C\]varespladib methyl.
What is the current status of trial NCT01359605?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2011-06. Estimated completion is 2011-07.
What interventions are being tested in trial NCT01359605?
The interventions under investigation include: varespladib methyl (DRUG).
Who is sponsoring clinical trial NCT01359605?
This trial is sponsored by Anthera Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.